Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count.

[1]  Helen M. Chun,et al.  Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals , 2010, AIDS.

[2]  C. Bailey,et al.  Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  E. Overton.  ACTG 5220: Hepatitis B Vaccine Responses in HIV-Infected Persons Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) , 2008 .

[4]  M. Roediger,et al.  Increasing Age at HIV Seroconversion From 18 to 40 Years Is Associated With Favorable Virologic and Immunologic Responses to HAART , 2008, Journal of acquired immune deficiency syndromes.

[5]  A. Phillips,et al.  Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.

[6]  M. Landrum,et al.  Routine Vaccination in HIV-Infected Adults , 2008 .

[7]  M. Proschan,et al.  Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. , 2008, The Journal of infectious diseases.

[8]  F. Pereyra,et al.  CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms , 2007, Nature Immunology.

[9]  JD Lundgren,et al.  Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study , 2007, The Lancet.

[10]  L. Aurpibul,et al.  Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. , 2007, Vaccine.

[11]  C. Fraser,et al.  CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.

[12]  P. Hunt.  Role of immune activation in HIV pathogenesis , 2007, Current HIV/AIDS reports.

[13]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[14]  R. Grant,et al.  Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  G. Ruiz-Palacios,et al.  Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses , 2006, AIDS research and therapy.

[16]  W. Jilg,et al.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. , 2006, Vaccine.

[17]  W. Powderly,et al.  Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Angel,et al.  CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults , 2005, AIDS.

[19]  P. Briss,et al.  Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. , 2005, American journal of preventive medicine.

[20]  P. Sax,et al.  Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. , 2005, The Journal of infectious diseases.

[21]  A. Barone,et al.  Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. , 2005, Vaccine.

[22]  J. Benito,et al.  Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[23]  V. Soriano,et al.  Erratum: Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel (AIDS (2005) 19 (221-240)) , 2005 .

[24]  H. Fields,et al.  The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. , 2004, Virology.

[25]  A. Moorman,et al.  Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Z. Grossman,et al.  Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia , 2004, AIDS.

[27]  J. Mascola,et al.  Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort , 2003, AIDS.

[28]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[29]  R. Dersimonian,et al.  Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. , 2003, Journal of acquired immune deficiency syndromes.

[30]  Maria Deloria-Knoll,et al.  Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.

[31]  D. D. Jarlais,et al.  Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. , 2002, Addiction.

[32]  COST-EFFECTIVENESS IMPLICATIONS OF THE TIMING OF ANTIRETROVIRAL THERAPY IN HIV-INFECTED ADULTS , 2002 .

[33]  K. Holmes,et al.  Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America* , 2002, Annals of Internal Medicine.

[34]  V. Soriano,et al.  Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.

[35]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[36]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[37]  G. Poland,et al.  A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. , 1997, The Journal of infectious diseases.

[38]  M. Osterholm,et al.  Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. , 1993, JAMA.

[39]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[40]  C. Morimoto,et al.  The cellular basis for lack of antibody response to hepatitis B vaccine in humans , 1991, The Journal of experimental medicine.

[41]  A. Katz,et al.  Genetic prediction of nonresponse to hepatitis B vaccine. , 1989, The New England journal of medicine.

[42]  E. Tanzi,et al.  Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. , 1989, Archives of internal medicine.

[43]  M. Tong,et al.  Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. , 1988, JAMA.

[44]  H. Handsfield,et al.  Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. , 1988, Annals of internal medicine.

[45]  S. Hadler,et al.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. , 1986, The New England journal of medicine.

[46]  U. Parashar.  Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) : Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2006 .

[47]  J. Bartlett.  Public health guidance for community-level preparedness and response to severe acute respiratory syndrome (SARS) , 2004 .

[48]  David R. Holtgrave,et al.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. , 2002, Annals of internal medicine.